Award Abstract # 2033939
RAPID: Molecular Insights into the SARS-CoV-2 Spike Protein Activation via a Novel Interaction with a Human Cell Surface Target Protein

NSF Org: MCB
Division of Molecular and Cellular Biosciences
Recipient: SCRIPPS RESEARCH INSTITUTE
Initial Amendment Date: June 9, 2020
Latest Amendment Date: June 9, 2020
Award Number: 2033939
Award Instrument: Standard Grant
Program Manager: Richard Cyr
rcyr@nsf.gov
 (703)292-8440
MCB
 Division of Molecular and Cellular Biosciences
BIO
 Directorate for Biological Sciences
Start Date: June 15, 2020
End Date: May 31, 2021 (Estimated)
Total Intended Award Amount: $199,844.00
Total Awarded Amount to Date: $199,844.00
Funds Obligated to Date: FY 2020 = $199,844.00
History of Investigator:
  • Tina Izard (Principal Investigator)
    izard@scripps.edu
Recipient Sponsored Research Office: The Scripps Research Institute
10550 N TORREY PINES RD
LA JOLLA
CA  US  92037-1000
(858)784-8653
Sponsor Congressional District: 50
Primary Place of Performance: The Scripps Research Institute - Florida
130 Scripps Way, 2C1
Jupiter
FL  US  33458-5284
Primary Place of Performance
Congressional District:
21
Unique Entity Identifier (UEI): PHZJFZ32NKH4
Parent UEI:
NSF Program(s): COVID-19 Research
Primary Program Source: 010N2021DB R&RA CARES Act DEFC N
Program Reference Code(s): 096Z, 7465, 7914
Program Element Code(s): 158Y00
Award Agency Code: 4900
Fund Agency Code: 4900
Assistance Listing Number(s): 47.074
Note: This Award includes Coronavirus Aid, Relief, and Economic Security (CARES) Act funding.

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus that belongs to the subgenus sarbecvirus of Coronaviridae. Members of the Coronaviridae family include the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which are the responsible human pathogens for the common cold and other emerging severe respiratory conditions. SARS-CoV and SARS-CoV-2 attach to the host cells by binding to the angiotensin converting enzyme 2 (ACE2) receptor. Viral entry is facilitated by the binding of the receptor binding domain (RBD) of the coronavirus spike protein to the ACE2 receptor. However, SARS-CoV-2 targets type II alveolar cells in the lung that have relatively low ACE2 expression compared to ACE2 expression in other organs. Thus, other co-receptors have been identified that are targeted by the virus and which likely provide for an alternative entry point for the virus. While SARS-CoV-2 infects fewer organs compared to SARS-CoV, the mechanisms remain inconclusive. This research project will provide structural insights into the novel role of a human cell surface protein in SARS-CoV-2 entry and replication. There is an urgent need for gaining insight into this possible second entry point for the virus into cells. Additionally, this project includes an educational outreach component geared towards the underrepresented minorities and in particular the younger population, an incredibly important sub popular who might be underestimating the impact of SARS.

This research project will use the first 300 kV cryo Atomic Resolution Microscope (ARM), installed to date in the US, to determine the near atomic resolution structures of the novel interaction between a human cell surface protein and the SARS-CoV-2 spike protein. Biochemical assays will additionally validate the structural findings. Thus, significant mechanistic insights into viral pathogenesis will be published rapidly from data obtained on a new cryo-electron microscope in the US that has aided near atomic resolution insights into many biological processes from several laboratories overseas, including from Europe and Asia. By determining the mechanistic insights into how SARS-CoV-2 infects fewer organs compared to SARS-CoV, the findings obtained in this research project could explain the lower mortality of SARS-CoV-2 compared to SARS-CoV. Collectively, the structural insights into the mechanism of the interaction of the SARS-CoV-2 spike protein with a human cell surface protein will: (i) further the understanding on how COVID-19 is spreading, (ii) shed light onto some of the key differences of SARS-CoV-2 versus SARS-CoV, and (iii) provide mechanistic insights into the higher transmissibility of SARS-CoV-2. Such virus-host study will contribute to a broader understanding of viral pathogenesis.

This RAPID award is made by the Cellular Dynamics and Functionl Program in the Division of Molecular and Cellular Biosciences, using funds from the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

PUBLICATIONS PRODUCED AS A RESULT OF THIS RESEARCH

Note:  When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

Zhang, Lizhou and Jackson, Cody B. and Mou, Huihui and Ojha, Amrita and Peng, Haiyong and Quinlan, Brian D. and Rangarajan, Erumbi S. and Pan, Andi and Vanderheiden, Abigail and Suthar, Mehul S. and Li, Wenhui and Izard, Tina and Rader, Christoph and Farz "SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity" Nature Communications , v.11 , 2020 https://doi.org/10.1038/s41467-020-19808-4 Citation Details

PROJECT OUTCOMES REPORT

Disclaimer

This Project Outcomes Report for the General Public is displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus that belongs to the subgenus sarbecvirus of Coronaviridae. Members of the Coronaviridae family include the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which are the responsible human pathogens for the common cold and other emerging severe respiratory conditions. SARS-CoV and SARS-CoV-2 attach to the host cells by binding to the angiotensin converting enzyme 2 (ACE2) receptor. Viral entry is facilitated by the binding of the receptor binding domain (RBD) of the coronavirus spike protein to the ACE2 receptor. However, SARS-CoV-2 targets type II alveolar cells in the lung that have relatively low ACE2 expression compared to ACE2 expression in other organs. Thus, other co-receptors have been identified that are targeted by the virus. While SARS-CoV-2 infects fewer organs compared to SARS-CoV, the mechanisms remain inconclusive. This research project sought to provide structural insights into the role a new and understudied human cell surface protein in SARS-CoV-2 entry and replication. Additionally, this project includes an educational outreach component geared towards the underrepresented minorities and in particular the younger population, an incredibly important sub popular who might be underestimating the impact of SARS.

While we could not confirm the interaction of the spike protein with integrin, we showed that the genetic point mutation D614G of the spike protein increases the ability of the coronavirus to infect human cells.

We published our findings in a peer reviewed journal in 2020 (Nature Communications, 11:6013) and our work was highlighted in a press release:

https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html

 

 

 


Last Modified: 09/24/2021
Modified by: Tina Izard

Please report errors in award information by writing to: awardsearch@nsf.gov.

Print this page

Back to Top of page